Get Benzinga's Best Trading Ideas For Free

MannKind Corporation (MNKD) 7.34 +0.05

Trade MNKD
NOW!
Last Trade:6.91Short Ratio:11.10
Last Trade Time:4:00pmDay Range:6.77 - 7.10
Ask:7.34Year Range:4.76 - 12.30
Bid:6.55One Year Target:10.00
Open:6.79Exchange:NGM
Volume:1114898EBITDA:-174.0M
Prev. Close:6.86Market Cap:784.0M
50 Day Moving:6.3436Div Yield:
200 day moving:7.4883PE:

MannKind Corporation to Hold 2010 Second Quarter Financial Results Conference Call on August 2, 2010

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) will release its 2010 second quarter financial results on Monday, August 2, 2010.

MannKind Corporation to Hold 2010 Second Quarter Financial Results

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) will release its 2010 second quarter financial results on Monday, August 2, 2010.

Late Pop Impressive 07-20-2010

Are Earnings Weighing In? 07-20-2010

Mankind Surges On Acceptance Of Resubmitted Application For Afrezza

Shares of Mannkind Inc (NASDAQ: MNKD) are moving up after the US Food and Drug Administration accepted the company’s resubmitted application for the inhaled insulin product Afrezza.

FDA Accepts AFREZZA Complete Response Resubmission and Sets Target Action Date

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (NASDAQ: MNKD) today announced that it has submitted, and the U.S.

PennyOmega.com Announces Stock Alert on DARA, ORFG, MNKD, SNRY

(via COMTEX News Network)-- PennyOmega tracks stocks daily and is pleased to offer its hot stock alerts. Investors can receive FREE Stock Alerts by visiting PennyOmega.com at the following link: http://www.PennyOmega.com.

AFREZZA™ Demonstrates Long-Term Efficacy in Controlling Blood Sugar Levels in Patients with Type 2 Diabetes

ORLANDO, Fla.--(BUSINESS WIRE)-- AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence o

AFREZZA™ Suppresses Endogenous Glucose Production More Rapidly Than Currently Available Insulin Therapy

ORLANDO, Fla.--(BUSINESS WIRE)-- AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, provides more rapid suppression of endogenous glucose production (EGP) after a meal than the subcutaneously-injected insul